Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Low-FODMAP diet offers hope for celiac sufferers with ongoing gut pain

NCT ID NCT03678935

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether cutting out certain carbs (FODMAPs) can help people with celiac disease who still have stomach issues even after following a gluten-free diet. Researchers surveyed and then ran a controlled trial with 80 adults who had celiac disease and irritable bowel-like symptoms. The goal was to see if a low-FODMAP diet could reduce their ongoing gut discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Oct 2018

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Coeliac disease * Adherent to GFD for at least 12 months * Strictly adherent to GFD * Normal coeliac disease (CD) serology and duodenal biopsy (Marsh 0-1) * Persistent GI-symptoms defined by GSRS-IBS score of 30 or more * Living less than 2 hour from study centre Exclusion Criteria: * Pregnancy or lactating women * Use of immunomodulating drugs in the last 3 months * Use of anti-inflammatory drugs in the last 3 months * Use of antacid drugs in the last 2 months * Ongoing infection (mild infection such as upper airway infection is ok) * Other chronical bowel disorder (except for IBS) * Previous tried the LFD with guidance of a dietician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Celiac disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital

    Oslo, Postboks PB 4950 Nydalen, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.